These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 34867987)

  • 21. The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes.
    Dammeijer F; van Gulijk M; Mulder EE; Lukkes M; Klaase L; van den Bosch T; van Nimwegen M; Lau SP; Latupeirissa K; Schetters S; van Kooyk Y; Boon L; Moyaart A; Mueller YM; Katsikis PD; Eggermont AM; Vroman H; Stadhouders R; Hendriks RW; Thüsen JV; Grünhagen DJ; Verhoef C; van Hall T; Aerts JG
    Cancer Cell; 2020 Nov; 38(5):685-700.e8. PubMed ID: 33007259
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer.
    Beumer-Chuwonpad A; Taggenbrock RLRE; Ngo TA; van Gisbergen KPJM
    Cells; 2021 Aug; 10(9):. PubMed ID: 34571883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overcoming anti-PD-1/PD-L1 immune checkpoint blockade resistance: the role of macrophage, neutrophils and mast cells in the tumor microenvironment.
    Kwantwi LB
    Clin Exp Med; 2023 Nov; 23(7):3077-3091. PubMed ID: 37022584
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined immune checkpoint blockade increases CD8+CD28+PD-1+ effector T cells and provides a therapeutic strategy for patients with neuroblastoma.
    Shirinbak S; Chan RY; Shahani S; Muthugounder S; Kennedy R; Hung LT; Fernandez GE; Hadjidaniel MD; Moghimi B; Sheard MA; Epstein AL; Fabbri M; Shimada H; Asgharzadeh S
    Oncoimmunology; 2021 Jan; 10(1):1838140. PubMed ID: 33489468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Resident Memory T Cells for Cancer Immunotherapy.
    Blanc C; Hans S; Tran T; Granier C; Saldman A; Anson M; Oudard S; Tartour E
    Front Immunol; 2018; 9():1722. PubMed ID: 30100906
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tissue-resident memory T cells in breast cancer control and immunotherapy responses.
    Byrne A; Savas P; Sant S; Li R; Virassamy B; Luen SJ; Beavis PA; Mackay LK; Neeson PJ; Loi S
    Nat Rev Clin Oncol; 2020 Jun; 17(6):341-348. PubMed ID: 32112054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual checkpoint blockade of CD47 and PD-L1 using an affinity-tuned bispecific antibody maximizes antitumor immunity.
    Chen SH; Dominik PK; Stanfield J; Ding S; Yang W; Kurd N; Llewellyn R; Heyen J; Wang C; Melton Z; Van Blarcom T; Lindquist KC; Chaparro-Riggers J; Salek-Ardakani S
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34599020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue-resident memory T cells at the center of immunity to solid tumors.
    Amsen D; van Gisbergen KPJM; Hombrink P; van Lier RAW
    Nat Immunol; 2018 Jun; 19(6):538-546. PubMed ID: 29777219
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition of MAN2A1 Enhances the Immune Response to Anti-PD-L1 in Human Tumors.
    Shi S; Gu S; Han T; Zhang W; Huang L; Li Z; Pan D; Fu J; Ge J; Brown M; Zhang P; Jiang P; Wucherpfennig KW; Liu XS
    Clin Cancer Res; 2020 Nov; 26(22):5990-6002. PubMed ID: 32723834
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 32. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade.
    Liu Y; Cai J; Liu W; Lin Y; Guo L; Liu X; Qin Z; Xu C; Zhang Y; Su X; Deng K; Yan G; Liang J
    Cell Death Dis; 2020 Dec; 11(12):1062. PubMed ID: 33311488
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Irreversible electroporation augments checkpoint immunotherapy in prostate cancer and promotes tumor antigen-specific tissue-resident memory CD8+ T cells.
    Burbach BJ; O'Flanagan SD; Shao Q; Young KM; Slaughter JR; Rollins MR; Street TJL; Granger VE; Beura LK; Azarin SM; Ramadhyani S; Forsyth BR; Bischof JC; Shimizu Y
    Nat Commun; 2021 Jun; 12(1):3862. PubMed ID: 34162858
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The nexus of dynamic T cell states and immune checkpoint blockade therapy in the periphery and tumor microenvironment.
    Luo H; Wang W; Mai J; Yin R; Cai X; Li Q
    Front Immunol; 2023; 14():1267918. PubMed ID: 37881432
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Photo-induced crosslinked and anti-PD-L1 peptide incorporated liposomes to promote PD-L1 multivalent binding for effective immune checkpoint blockade therapy.
    Lee Y; Song S; Yang S; Kim J; Moon Y; Shim N; Yoon HY; Kim S; Shim MK; Kim K
    Acta Pharm Sin B; 2024 Mar; 14(3):1428-1440. PubMed ID: 38487005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tissue-resident memory T cells in tissue homeostasis, persistent infection, and cancer surveillance.
    Gebhardt T; Palendira U; Tscharke DC; Bedoui S
    Immunol Rev; 2018 May; 283(1):54-76. PubMed ID: 29664571
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Resident Memory T Cells in the Tumor Microenvironment.
    Williams JB; Kupper TS
    Adv Exp Med Biol; 2020; 1273():39-68. PubMed ID: 33119875
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
    Jiang Y; Zhao X; Fu J; Wang H
    Front Immunol; 2020; 11():339. PubMed ID: 32226426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.